Price$76.65+13.72 (+21.79%)
2026-04-142026-07-17
News · 26 weeks78-78%
2026-01-252026-07-19
Mix4690d
- Insider27(59%)
- Other10(22%)
- SEC Filings4(9%)
- Earnings2(4%)
- Analyst2(4%)
- Leadership1(2%)
Latest news
25 items- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with DiabetesDexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5. Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713940133/en/Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility. D
- PRDexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern TimeDexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the star
- INSIDERExecutive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Further Advances Vision of Glucose Biosensing for AllAt Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States.The company also announced details regarding the rollout of its fully reimagined Stelo app experience launching in July in the US, helping make glucose insights more approachable and actionable for people seeking better health.Expanded international availability of Stelo is also planned for the United Kingdom, Australia, New Zealand and South Korea starting later this year and will continue into 2027.DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of mil
- ANALYSTDeutsche Bank initiated coverage on Dexcom with a new price targetDeutsche Bank initiated coverage of Dexcom with a rating of Buy and set a new price target of $86.00
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using InsulinDexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst
- INSIDEREVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. Early access launch of a completely reimagined Stelo app will define a new era of glucose tracking for all people not on insulin seeking better health. Acquisition of Nutrisense will strengthen Dexcom's ability to provide personalized nutrition education and coaching to improve diabetes management and help further establish CGM as an effective tool for preventative care. DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforci
- PRDexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User ExperienceCompany establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its techno
- INSIDERDirector Altman Steven R was granted 5,565 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Augustinos Nicholas was granted 5,575 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Foletta Mark G was granted 6,331 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Collins Richard Alexander was granted 5,605 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Gala Renee D was granted 5,605 shares, increasing direct ownership by 81% to 12,486 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- SECDexCom Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DEXCOM INC (0001093557) (Filer)
- SECSEC Form SD filed by DexCom Inc.SD - DEXCOM INC (0001093557) (Filer)
- INSIDERPresident, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.34% to 420,359 units (SEC Form 4) (withholding tax)4 - DEXCOM INC (0001093557) (Issuer)
DXCM FAQ
7 questionsWhat does DexCom Inc. do?
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop...Where does DXCM stock trade?
DexCom Inc. (DXCM) is listed on NASDAQ.What sector and industry is DXCM in?
DexCom Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did DexCom Inc. go public?
DexCom Inc. (DXCM) completed its IPO in 2005.What are analysts saying about DXCM?
DexCom Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Buy on 2026-06-23.What companies are similar to DXCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DXCM side-by-side with any of them on Quantisnow.How can I track DXCM on Quantisnow?
Quantisnow aggregates DexCom Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DXCM to receive live email and push alerts on every new disclosure.